Differences in Treatment Decision-Making in Frontline Management of Lower-Risk Myelodysplastic Syndromes between Academic and Community Practice Settings: Results from a Nationwide Survey

Background Lower-risk myelodysplastic syndromes (LR-MDS) are characterized by anemia in the majority of patients (pts), with more than half of pts becoming red blood cell (RBC) transfusion dependent. A goal of therapy is to alleviate cytopenia and its related complications. We assessed differences i...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2024-11, Vol.144 (Supplement 1), p.3679-3679
Main Authors: Sekeres, Mikkael A., Venugopal, Sangeetha, Chandhok, Namrata S., Watts, Justin M., Bradley, Terrence, Taylor, Justin, Sallman, David, Xie, Zhuoer, Padron, Eric, Sullivan, Shelby, Zyborowicz, Emily, Carter, Jeffrey, Heggen, Cherilyn, Gurska, Lindsay, Komrokji, Rami S.
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Lower-risk myelodysplastic syndromes (LR-MDS) are characterized by anemia in the majority of patients (pts), with more than half of pts becoming red blood cell (RBC) transfusion dependent. A goal of therapy is to alleviate cytopenia and its related complications. We assessed differences in clinical information used to guide LR-MDS treatment decision-making and barriers to treatment decisions between community and academic hematology/oncology providers in a nationwide survey. Methods During April 2024, a survey was sent twice two days apart to 29,192 hematology/oncology healthcare providers (HCPs), with survey access denied upon reaching the pre-defined goal (1% completion rate). Means and ranges are presented for summary statistics, and comparisons between groups were conducted using Chi-square statistics, with p-values
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2024-203444